[1] Winslow, R. (2000). Birth of a blockbuster: Lipitor’s unlikely route out of the lab. Wall Street Journal, 24.
[2] Endo, A. (1992). The discovery and development of HMG-CoA reductase inhibitors. Journal of lipid research, 33(11), 1569-1582.
[3] Rosa, G. M., Carbone, F., Parodi, A., Massimelli, E. A., Brunelli, C., Mach, F., ... & Montecucco, F. (2014). Update on the efficacy of statin treatment in acute coronary syndromes. European journal of clinical investigation, 44(5), 501-515.
[4] Hongbao, M., & Yan, Y. Streptozotocin, Atorvastatin, Renal, Diabetes and Related Factors.
[5] Adams, S. P., Tsang, M., & Wright, J. M. (2012). Lipid lowering efficacy of atorvastatin. Cochrane database of systematic reviews, (12).
[6] Hermann, M., Bogsrud, M. P., Molden, E., Åsberg, A., Mohebi, B. U., Ose, L., & Retterstøl, K. (2006). Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several‐fold in patients with atorvastatin‐induced myopathy. Clinical Pharmacology & Therapeutics, 79(6), 532-539.
[7] Christians, U., Jacobsen, W., & Floren, L. C. (1998). Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?. Pharmacology & therapeutics, 80(1), 1-34.
[8] Tobert, J. A. (2003). Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nature reviews Drug discovery, 2(7), 517.
[9] Macedo, A. F., Taylor, F. C., Casas, J. P., Adler, A., Prieto-Merino, D., & Ebrahim, S. (2014). Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. BMC medicine, 12(1), 51.
[10] Roche, V. F. (2005). Antihyperlipidemic statins: a self-contained, clinically relevant medicinal chemistry lesson. American Journal of Pharmaceutical Education, 69(4), 77.
[11] Istvan, E. S., & Deisenhofer, J. (2001). Structural mechanism for statin inhibition of HMG-CoA reductase. Science, 292(5519), 1160-1164.
[12] Shepherd, J., Hunninghake, D. B., Barter, P., McKenney, J. M., & Hutchinson, H. G. (2003). Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. The American journal of cardiology, 91(5), 11-17.
[13] Liu, J., Zhang, J., Shi, Y., Grimsgaard, S., Alraek, T., & Fønnebø, V. (2006). Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chinese medicine, 1(1), 4.
[14] Daugherty, M., Polanuyer, B., Farrell, M., Scholle, M., Lykidis, A., de Crécy-Lagard, V., & Osterman, A. (2002). Complete reconstitution of the human coenzyme A biosynthetic pathway via comparative genomics. Journal of Biological Chemistry, 277(24), 21431-21439.
[15] Bachhawat, B. K., Austin, J., & Armstrong, D. (2015). A Cerebroside Sulphotransferase Deficiency in a Human Disorder of Myelin. The National medical journal of India, 28(3), 161-164.
[16] Surolia, A. (1997). An outstanding scientist and a splendid human being: Prof Bimal Kumar Bachhawat. Glycobiology, 7(4), R5-R6.
[17] Stancu, C., & Sima, A. (2001). Statins: mechanism of action and effects. Journal of cellular and molecular medicine, 5(4), 378-387.
[18] Puccetti, L., Pasqui, A. L., Pastorelli, M., Bova, G., Cercignani, M., Palazzuoli, A., ... & Bruni, F. (2002). Time‐dependent effect of statins on platelet function in hypercholesterolaemia. European journal of clinical investigation, 32(12), 901-908.
[19] Roth, B. D. (2002). 1 The Discovery and Development of Atorvastatin, a Potent Novel Hypolipidemic Agent. In Progress in medicinal chemistry (Vol. 40, pp. 1-22). Elsevier.
[20] Miziorko, H. M. (2011). Enzymes of the mevalonate pathway of isoprenoid biosynthesis. Archives of biochemistry and biophysics, 505(2), 131-143.
[21] Frantz Jr, I. D., & Schroepfer Jr, G. J. (1967). Sterol biosynthesis. Annual review of biochemistry, 36(1), 691-726.
[22] Hosokawa, G., Patterson, G. W., & Lusby, W. R. (1984). Effects of triarimol, tridermorph and triparanol on sterol biosynthesis in carrot, tobacco and soybean suspension cultures. Lipids, 19(6), 449-456.
[23] Singh, P., Saxena, R., Srinivas, G., Pande, G., & Chattopadhyay, A. (2013). Cholesterol biosynthesis and homeostasis in regulation of the cell cycle. PloS one, 8(3), e58833.
[24] BEYER, R. S., & JENSEN, L. S. (1993). The hypocholesterolemic agent dichloroacetate increases egg cholesterol content of laying hens. Poultry science, 72(6), 1063-1069.
[25] Boots, M. R., Boots, S. G., Noble, C. M., & Guyer, K. E. (1973). Hypocholesterolemic Agents II: Inhibition of β-Hydroxy-β-methylglutaryl Coenzyme A Reductase by Arylalkyl Hydrogen Succinates and Glutarates. Journal of pharmaceutical sciences, 62(6), 952-957.
[26] Brown, A. G., Smale, T. C., King, T. J., Hasenkamp, R., & Thompson, R. H. (1976). Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillium brevicompactum. Journal of the Chemical Society, Perkin Transactions 1, (11), 1165-1170.
[27] Endo, A., Tsujita, Y., Kuroda, M., & TANZAWA, K. (1977). Inhibition of Cholesterol Synthesis in vitro and in vivo by ML‐236A and ML‐236B, Competitive Inhibitors of 3‐Hydroxy‐3‐methylglutaryl‐Coenzyme A Reductase. European Journal of Biochemistry, 77(1), 31-36.
[28] Alberts, A. W., Chen, J., Kuron, G., Hunt, V., Huff, J., Hoffman, C., ... & Patchett, A. (1980). Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proceedings of the National Academy of Sciences, 77(7), 3957-3961.
[29] Endo, A. (1979). Monacolin K, a new hypocholesterolemic agent produced by a Monascus species. The Journal of antibiotics, 32(8), 852-854..
[30] Hoffman, W. F., Alberts, A. W., Anderson, P. S., Chen, J. S., Smith, R. L., & Willard, A. K. (1986). 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 4. Side-chain ester derivatives of mevinolin. Journal of medicinal chemistry, 29(5), 849-852.
[31] Paal, C. (1885). Synthese von Thiophen‐und Pyrrolderivaten. Berichte der deutschen chemischen Gesellschaft, 18(1), 367-371.
[32] Narasaka, K., & Pai, H. C. (1980). Stereoselective synthesis of meso (or erythro) 1, 3-diols from β-hydroxyketones. Chemistry Letters, 9(11), 1415-1418.
[33] Rádl, S., Stach, J., & Hajicek, J. (2002). An improved synthesis of 1, 1-dimethylethyl 6-cyanomethyl-2, 2-dimethyl-1, 3-dioxane-4-acetate, a key intermediate for atorvastatin synthesis. Tetrahedron letters, 43(11), 2087-2090.
[34] Bodurow, C. C., Boyer, B. D., Brennan, J., Bunnell, C. A., Burks, J. E., Carr, M. A., ... & Graves, B. J. (1989). An enantioselective synthesis of loracarbef (LY163892/KT3777). Tetrahedron Letters, 30(18), 2321-2324.
[35] Hu, F. B., Stampfer, M. J., Manson, J. E., Rimm, E., Colditz, G. A., Rosner, B. A., ... & Willett, W. C. (1997). Dietary fat intake and the risk of coronary heart disease in women. New England journal of medicine, 337(21), 1491-1499.
[36] Chen, K. M., Hardtmann, G. E., Prasad, K., Repič, O., & Shapiro, M. J. (1987). 1, 3-syn diastereoselective reduction of β-hydroxyketones utilizing alkoxydialkylboranes. Tetrahedron letters, 28(2), 155-158.
[37] Kumar, P., Deshmukh, A. N., Upadhyay, R. K., & Gurjar, M. K. (2005). A simple and practical approach to enantiomerically pure (S)-3-hydroxy-γ-butyrolactone: synthesis of (R)-4-cyano-3-hydroxybutyric acid ethyl ester. Tetrahedron: Asymmetry, 16(16), 2717-2721.
[38] Pfruender, H., Amidjojo, M., Hang, F., & Weuster-Botz, D. (2005). Production of Lactobacillus kefir cells for asymmetric synthesis of a 3, 5-dihydroxycarboxylate. Applied microbiology and biotechnology, 67(5), 619-622.
[39] Patel, R. N., Banerjee, A., McNamee, C. G., Brzozowski, D., Hanson, R. L., & Szarka, L. J. (1993). Enantioselective microbial reduction of 3, 5-dioxo-6-(benzyloxy) hexanoic acid, ethyl ester. Enzyme and microbial technology, 15(12), 1014-1021.
[40] Wolberg, M., Hummel, W., Wandrey, C., & Müller, M. (2000). Highly regio‐and enantioselective reduction of 3, 5‐dioxocarboxylates. Angewandte Chemie International Edition, 39(23), 4306-4308.
[41] Gijsen, H. J., & Wong, C. H. (1994). Unprecedented asymmetric aldol reactions with three aldehyde substrates catalyzed by 2-deoxyribose-5-phosphate aldolase. Journal of the American Chemical Society, 116(18), 8422-8423.
[42] Liu, J., Hsu, C. C., & Wong, C. H. (2004). Sequential aldol condensation catalyzed by DERA mutant Ser238Asp and a formal total synthesis of atorvastatin. Tetrahedron letters, 45(11), 2439-2441.
[43] Greenberg, W. A., Varvak, A., Hanson, S. R., Wong, K., Huang, H., Chen, P., & Burk, M. J. (2004). Development of an efficient, scalable, aldolase-catalyzed process for enantioselective synthesis of statin intermediates. Proceedings of the National Academy of Sciences, 101(16), 5788-5793.
[44] DeSantis, G., Zhu, Z., Greenberg, W. A., Wong, K., Chaplin, J., Hanson, S. R., ... & Robertson, D. E. (2002). An enzyme library approach to biocatalysis: development of nitrilases for enantioselective production of carboxylic acid derivatives. Journal of the American Chemical Society, 124(31), 9024-9025.
[45] DeSantis, G., Wong, K., Farwell, B., Chatman, K., Zhu, Z., Tomlinson, G., ... & Kretz, K. (2003). Creation of a productive, highly enantioselective nitrilase through gene site saturation mutagenesis (GSSM). Journal of the American Chemical Society, 125(38), 11476-11477.
[46] Short, J. M. (2001). U.S. Patent No. 6,171,820. Washington, DC: U.S. Patent and Trademark Office.
[47] Bergeron, S., Chaplin, D. A., Edwards, J. H., & Ellis, B. S. (2006). W., Hill CL, Holt-Tiffin K., Knight JR, Mahoney T., Osborne AP, Ruecroft G. Org. Proc. Res. Dev, 10, 661.
[48] Sun, F., Xu, G., Wu, J., & Yang, L. (2006). Efficient lipase-catalyzed kinetic resolution of 4-arylmethoxy-3-hydroxybutanenitriles: application to an expedient synthesis of a statin intermediate. Tetrahedron: Asymmetry, 17(20), 2907-2913.
[49] Wang, G., & Hollingsworth, R. I. (1999). Synthetic routes to L-carnitine and L-gamma-amino-beta-hydroxybutyric acid from (S)-3-hydroxybutyrolactone by functional group priority switching. Tetrahedron: Asymmetry, 10(10), 1895-1901.
[50] Lee, S. H., Park, O. J., & Uh, H. S. (2008). A chemoenzymatic approach to the synthesis of enantiomerically pure (S)-3-hydroxy-γ-butyrolactone. Applied microbiology and biotechnology, 79(3), 355-362.
[51] Goldberg, S., Guo, Z., Chen, S., Goswami, A., & Patel, R. N. (2008). Synthesis of ethyl-(3R, 5S)-dihydroxy-6-benzyloxyhexanoates via diastereo-and enantioselective microbial reduction: Cloning and expression of ketoreductase III from Acinetobacter sp. SC 13874. Enzyme and Microbial Technology, 43(7), 544-549.
[52] Majerić Elenkov, M., Tang, L., Hauer, B., & Janssen, D. B. (2006). Sequential kinetic resolution catalyzed by halohydrin dehalogenase. Organic letters, 8(19), 4227-4229.
[53] Patel, J. M. (2009). Biocatalytic synthesis of atorvastatin intermediates. Journal of Molecular Catalysis B: Enzymatic, 61(3-4), 123-128.
[54] Hu, L., Xiong, F., Chen, X., Chen, W., He, Q., & Chen, F. (2013). Synthetic studies on statins. Part 1: a short and cyanide-free synthesis of atorvastatin calcium via an enantioselective aldol strategy. Tetrahedron: Asymmetry, 24(4), 207-211.
[55] Su, Z., Wen, J., Dente, L., Velde, R. V. D., Wang, L., Ma, Y., ... & Hu, Z. (2011). The Tibetan Plateau observatory of plateau scale soil moisture and soil temperature (Tibet-Obs) for quantifying uncertainties in coarse resolution satellite and model products. Hydrology and earth system sciences, 15(7), 2303-2316.
[56] Brower, P. L., Butler, D. E., Deering, C. F., Le, T. V., Millar, A., Nanninga, T. N., & Roth, B. D. (1992). The synthesis of (4R-cis)-1, 1-dimethylethyl 6-cyanomethyl-2, 2-dimethyl-1, 3-dioxane-4-acetate, a key intermediate for the preparation of CI-981, a highly potent, tissue selective inhibitor of HMG-CoA reductase. Tetrahedron Letters, 33(17), 2279-2282.
[57] Trost, B. M., & Brindle, C. S. (2010). The direct catalytic asymmetric aldol reaction. Chemical Society Reviews, 39(5), 1600-1632.
[58] Liuzzo, G., Biasucci, L. M., Gallimore, J. R., Grillo, R. L., Rebuzzi, A. G., Pepys, M. B., & Maseri, A. (1994). The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. New England journal of medicine, 331(7), 417-424.
[59] Narasaka, K., & Pai, F. C. (1984). Stereoselective reduction of β hydroxyketones to 1, 3-diols highly selective 1, 3-asymmetric induction via boron chelates. Tetrahedron, 40(12), 2233-2238.
[60] Black, D. M., Bakker-Arkema, R. G., & Nawrocki, J. W. (1998). An overview of the clinical safety profile of atorvastatin (Lipitor), a new HMG-CoA reductase inhibitor. Archives of internal Medicine, 158(6), 577-584.
[61] Maron, D. J., Fazio, S., & Linton, M. F. (2000). Current perspectives on statins. Circulation, 101(2), 207-213.
[62] Rosenson, R. S. (2004). Statins: can the new generation make an impression?. Expert opinion on emerging drugs, 9(2), 269-279.
[63] Ballantyne, C. M. (1998). Low-density lipoproteins and risk for coronary artery disease. The American journal of cardiology, 82(8), 3-12.
[64] Olsson, A. G., Pauciullo, P., Soska, V., Luley, C., Pieters, R. E., Broda, G., ... & Fluvastatin Study Group. (2001). Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial. Clinical therapeutics, 23(1), 45-61.
[65] Toth, P. P., Worthy, G., Gandra, S. R., Sattar, N., Bray, S., Cheng, L. I., ... & Deshpande, S. (2017). Systematic review and network meta‐analysis on the efficacy of evolocumab and other therapies for the management of lipid levels in hyperlipidemia. Journal of the American Heart Association, 6(10), e005367.